Concept of Pharmacovigilance, history and development of pharmacovigilance, WHO International drug monitoring programme, Pharmacovigilance programme of India
This presentation gives a brief knowledge of CIOMS, its history, missions and collaborations of CIOMS. This presentation also contains CIOMS organizational structure, detailed knowledge of CIOMS Former and Present Working Groups. This will also guide about CIOMS form, its reporting and details to be filled while reporting an ADR.
Organization and objectives of ICH, expedited reporting, ICSR, PSURs, post approval expedited reporting, pharmacovigilance Planning, good clinical practices
Concept of Pharmacovigilance, history and development of pharmacovigilance, WHO International drug monitoring programme, Pharmacovigilance programme of India
This presentation gives a brief knowledge of CIOMS, its history, missions and collaborations of CIOMS. This presentation also contains CIOMS organizational structure, detailed knowledge of CIOMS Former and Present Working Groups. This will also guide about CIOMS form, its reporting and details to be filled while reporting an ADR.
Organization and objectives of ICH, expedited reporting, ICSR, PSURs, post approval expedited reporting, pharmacovigilance Planning, good clinical practices
This presentation is a brief overview of ICH-GCP guidelines. Although ICH-GCP is a very vast topic, still this presentation will cover almost all the points. The reader will be able to discuss about the roles and responsibilities of various personnel in clinical trials.
pharmacovigilance, adverse effects, causality assessment,methods, who-umc method with case study, FOR DOWNLOAD PPT MAIL ME ON iamgauravchhabra@gmail.com
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCERamakrishna K
An introduction to pharmacovigilance, basic types like active pharmacovigilance and passive pharmacovigilance, purpose, adverse event reporting, data processing, causality, assessement, signal detection, risk management plans and analysis
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
Definitions, Severity assessment, Seriousness assessment
Naranjo algorithm, Preventability assessment
By
Ms. B. Mary Vishali
Department of Pharmacology
Pharmacovigilance is science of detection,
assessment, reporting and prevention of adverse
reactions to drug(s).
Major aims of pharmacovigilance are:
1. Early detection of hitherto unknown adverse
reactions and interactions
2. Detection of increases in frequency of (known)
adverse reactions
3. Identification of risk factors and possible
mechanisms underlying adverse reactions
4. Estimation of quantitative aspects of benefit/risk
analysis and dissemination of information needed to
improve drug prescribing and regulation.
This presentation is a brief overview of ICH-GCP guidelines. Although ICH-GCP is a very vast topic, still this presentation will cover almost all the points. The reader will be able to discuss about the roles and responsibilities of various personnel in clinical trials.
pharmacovigilance, adverse effects, causality assessment,methods, who-umc method with case study, FOR DOWNLOAD PPT MAIL ME ON iamgauravchhabra@gmail.com
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCERamakrishna K
An introduction to pharmacovigilance, basic types like active pharmacovigilance and passive pharmacovigilance, purpose, adverse event reporting, data processing, causality, assessement, signal detection, risk management plans and analysis
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
Definitions, Severity assessment, Seriousness assessment
Naranjo algorithm, Preventability assessment
By
Ms. B. Mary Vishali
Department of Pharmacology
Pharmacovigilance is science of detection,
assessment, reporting and prevention of adverse
reactions to drug(s).
Major aims of pharmacovigilance are:
1. Early detection of hitherto unknown adverse
reactions and interactions
2. Detection of increases in frequency of (known)
adverse reactions
3. Identification of risk factors and possible
mechanisms underlying adverse reactions
4. Estimation of quantitative aspects of benefit/risk
analysis and dissemination of information needed to
improve drug prescribing and regulation.
Adverse Event Reporting in Pharmacovigilance: Principles and ChallengesClinosolIndia
Adverse event reporting is a crucial component of pharmacovigilance, the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Here are the principles and challenges associated with adverse event reporting in pharmacovigilance:
Principles:
Timeliness: Adverse events should be reported promptly to ensure timely assessment and appropriate action. Reporting delays can hinder the detection of safety signals and the implementation of necessary interventions.
Completeness: Comprehensive reporting of all relevant information regarding the adverse event is vital. This includes patient demographics, medical history, drug details (name, dose, route of administration), onset and duration of the event, outcomes, and any concomitant medications.
Causality Assessment: Adverse events should be evaluated for their potential causality with the suspected drug. This involves considering factors such as temporal relationship, dechallenge/rechallenge information, and the presence of alternative explanations or confounding factors.
Confidentiality and Privacy: Adverse event reporting must uphold patient confidentiality and privacy. Personal identifiable information should be protected, and data should be handled in accordance with applicable data protection regulations.
Collaboration and Communication: Effective communication and collaboration between healthcare professionals, regulatory authorities, pharmaceutical companies, and patients are essential. Sharing information and feedback helps in improving patient safety and optimizing the understanding of adverse events.
detection methods of Adverse drug reactions, postal survey method, Reporting of Adverse drug reactions, Preventability assessment, predictability assessments
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
2. Candies and drugs?
• Popping pills like candies, are they really helping you, or causing some other
unwanted reactions?
• Anything entering our human body has to be safe, effective and helpful for our
body and should cure, treat, prevent or enhance our physical or mental well being.
• How do we ensure our drugs or vaccines are safe and effective and that they will
ultimately help us?
4. Drugs/Pills –Do they really help?
Why do we need to know and collect information on drugs or medicines?
a) Unexpected adverse reactions
b) Drug-Drug interactions
c) Long term efficacy
d) Quantify and recognise risk factors
Pharmacovigilance-The reason we humans invented it is-
To Keep our eyes open and our medicines safe.
5. Definition of Pharmacovigilance
Pharmacovigilance is the pharmacological science relating to the detection,
assessment, understanding and prevention of adverse effects, particularly long term and
short term side effect, of medicines (Source: The Importance of Pharmacovigilance,
WHO 2002).
-identifying new information about hazards associated with medicines
– preventing harm to patients
6. Basic Principles of Pharmacovigilance
What are adverse drug reactions(ADR) and adverse drug events(AE).
Difference between ADR and AE
Serious and Non serious ADR
Valid and non valid ADR
Unlisted and listed ADR
Workflow in PV for ADR
7. ADR and AE-Difference and Definition
Adverse events-(ADR)
An adverse event is any untoward medical occurrence in a patient administered a
medicinal product and which does not necessarily have to have a causal relationship
with this treatment.
Adverse drug reaction-(AE) A reaction, in contrast to an event, is characterized by the
fact that a causal relationship between the drug and the occurrence is suspected.
Stevens Johns Syndrome-caused by many infectious cause and by many drugs
including common drugs like acetaminophen (Tylenol, others), ibuprofen that we
routinely self prescribe.
8. Difference between ADR and AE
Adverse drug reaction Adverse event
Casual relation with drug may or may not
be
Casual relation with drug is suspected or is
possible
A patient admitted for anaphylactic
reaction to bee sting noted rash after
taking cetirizine
A healthy normal patient had rash 30
minutes after taking cetirizine
9. Minimum Criteria for Reporting
• For regulatory reporting, the minimum data elements for a case are –
– An identifiable reporter
– An identifiable patient
– An adverse reaction
– A suspect drug
10. Valid and Invalid ADR
Valid ADR Invalid ADR
Identifiable patient , product, event and
reporter
Non identifiable patient, product or event
and reporter
A 35 year old subject had rash after taking
penicillin as reported by Dr. ABC
“10 patients had rash after taking some
antibiotic” reported in newspaper
11. Adverse drug reactions(ADR)-reporters
– The case can be reported, while the drug is in the clinical trial or when it is in
the market. The case can be reported by eminent researchers through their
publication.
Type of reporter Description
Spontaneous Reporting When the drug is in market
Literature Reporting
Clinical Trial Reporting
Through publication i.e by
HCP (Health Care
Professional) and Non-HCP
When the drug is in clinical
trial
12. Serious and Non serious ADR
– ADR can be non serious when it does not fulfil seriousness criteria.
– ADR is serious when it fulfills following seriousness criteria-
1. Fatal.
2. Life threatening (NOTE: The term “life-threatening”
in the definition of “serious” refers to an event/reaction
in which the patient was at risk of death at the time of
the event/reaction; it does not refer to an event/
reaction which hypothetically might have caused death
if it were more severe).
3. Leads to or prolongs hospitalisation.
4. Leads to disability.
5. All birth defects / congenital anomalies.
6. Medically important.
13. Listed/Unlisted
• Using medical judgment in doing listed and unlistedness to report any possible drug
reactions to health authorities.
14. Listed/unlisted or expected/unexpected
Listed/expected Unlisted/Unexpected
Exact Event is present in CCDS, CCSI,I
B, SmPC, Package inserts
Exact event is not present in CCDS, CCSI,
IB, SmPC, Package inserts
Event of same etiology, cause, severity
and duration is present in above
mentioned documents
Event is of different cause, duration or
severity is present .
In CCDS pneumonia is present and
reported event is pneumonia it is listed
In CCDS only bacterial pneumonia is
present and reported event is viral
pneumonia then it is unlisted
17. Summary
• PV-To keep our medicines Safe and protect human race.
• PV steps involves collection of safety information by collecting adverse drug
reactions data and then making this data available to HCP and consumers.
• What are adverse drug reactions(ADR) and adverse drug events(AE).
• Difference between ADR and AE-done
• Serious and Non serious ADR
• Valid and non valid ADR
• Type of reporter
• Unlisted and listed ADR
18. Thank you
Have a Safe medications….
• Dr.shraddha M Bhange
• Senior Medical Reviewer